- Report
- August 2025
- 187 Pages
Global
From €3225EUR$3,545USD£2,755GBP
€3584EUR$3,939USD£3,061GBP
- Report
- August 2025
- 189 Pages
Global
From €3225EUR$3,545USD£2,755GBP
€3584EUR$3,939USD£3,061GBP
- Report
- June 2026
- 182 Pages
Global
From €3225EUR$3,545USD£2,755GBP
€3584EUR$3,939USD£3,061GBP
- Report
- January 2026
Global
From €4458EUR$4,900USD£3,808GBP
- Report
- January 2026
Global
From €4458EUR$4,900USD£3,808GBP
- Report
- March 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP
- Report
- February 2026
- 250 Pages
Global
From €4085EUR$4,490USD£3,489GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more